文献速递心脑血管急症重症综合管理与镇静镇痛

静脉重组人脑利钠肽治疗重度心力衰竭的疗效与安全性:前瞻性多中心临床研究

[Efficacy and safety of intravenous recombinant human brain natriuretic peptide in patients with severe heart failure: a prospective multicenter clinical study].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2017-01-01
一句话结论在常规治疗基础上加用rhBNP(负荷1.5 μg/kg后维持0.010-0.015 μg×kg-1×min-1)可改善重度心衰患者心功能并可能对肾功能有一定作用。

该前瞻性多中心研究纳入58家医院ICU/CCU中年龄>18岁、NYHA心功能III-IV级、急性心功能不全或慢性心功能不全急性加重患者408例,在常规治疗基础上给予rhBNP负荷量1.5 μg/kg(3-5分钟)后维持0.010-0.015 μg×kg-1×min-1持续3-7天。结果显示治疗后6小时NT-proBNP、PCWP、CVP较治疗前显著下降,治疗1天CO、3天LVEF显著升高,治疗3小时每小时尿量及第1、2天24小时尿量显著增加,30天SCr较治疗前显著降低。30天内再入ICU率2.7%、再住院率2.88%、再发心衰率1.43%、总病死率9.55%。结论认为rhBNP可显著改善心衰患者心功能,对肾功能有一定作用,治疗心功能不全有效且安全。

要点

  • 适用人群为ICU/CCU中年龄>18岁、NYHA III-IV级、急性心功能不全或慢性心功能不全急性加重患者,共408例。
  • rhBNP负荷量1.5 μg/kg静脉给药3-5分钟,随后维持0.010-0.015 μg×kg-1×min-1持续3-7天。
  • 治疗6小时后NT-proBNP、PCWP、CVP较治疗前显著下降(均P<0.05)。
  • 治疗1天CO、3天LVEF较治疗前显著升高(均P<0.05),且随给药时间延长逐渐升高。
  • 30天再入ICU率2.7%、再住院率2.88%、再发心衰率1.43%、总病死率9.55%。

适用人群与场景

  • 年龄>18岁、NYHA心功能III-IV级、急性心功能不全或慢性心功能不全急性加重、入住ICU/CCU的患者。

处置流程与药物剂量

  • 在常规治疗基础上给予rhBNP:负荷量1.5 μg/kg静脉给药3-5分钟,随后维持量0.010-0.015 μg×kg-1×min-1持续3-7天。

研究设计与关键结果

  • 前瞻性多中心研究,纳入58家医院408例患者(男241例、女167例),年龄28-95岁,平均(63.0±15.8)岁,50-70岁占46.8%。
  • 治疗6小时后NT-proBNP(μg×kg-1×min-1)由治疗前6403.41±5759.48降至4378.58±4082.29,PCWP(mmHg)由14.26±2.85降至12.41±2.21,CVP(mmHg)由11.45±3.45降至10.63±2.62,均P<0.05;随给药时间延长NT-proBNP、PCWP、CVP逐渐下降。
  • 治疗1天CO(mL)由治疗前4.40±0.92升至4.89±0.81,治疗3天LVEF由0.431±0.107升至0.465±0.100,均P<0.05;随给药时间延长CO和LVEF逐渐升高。
  • 治疗期间BUN和SCr无明显变化,治疗30天SCr(μmol/L)由治疗前132.62±75.60降至110.98±47.40,P<0.01。
  • 治疗3小时每小时尿量(mL)由治疗前89.60±53.49增至129.59±82.16,P=0.000;治疗第1天和第2天24小时尿量分别为2676.54±1006.83 mL和2678.74±975.97 mL,均较治疗前2150.36±283.76 mL显著增加,均P<0.01。
  • 7天内再入ICU率2.7%,30天内再住院率2.88%,30天内再发心衰率1.43%,30天总病死率9.55%。

证据类型、等级与局限

  • 证据类型:前瞻性多中心临床研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于ICU/CCU中年龄>18岁、NYHA III-IV级、急性心功能不全或慢性心功能不全急性加重的患者,在常规治疗基础上加用rhBNP(负荷1.5 μg/kg 3-5分钟,维持0.010-0.015 μg×kg-1×min-1持续3-7天)可改善心功能指标并可能对肾功能有一定作用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To explore the efficacy and safety of recombinant human brain natriuretic peptide (rhBNP) in the patients with severe heart failure (HF).

METHODS: A prospective multicenter study was conducted. Patients whose age > 18 years old, and with the New York Heart Association (NYHA) cardiac function grade over III-IV, acute cardiac insufficiency and the acute exacerbation of chronic cardiac insufficiency admitted to intensive care unit/cardiovascular care unit (ICU/CCU) of 58 Hospitals in China were enrolled. On the basis of the conventional treatment, all patients would be given rhBNP (neo adjuvant) with a loading dose of 1.5 μg/kg for 3-5 minutes, and followed by a maintenance dose of 0.010-0.015 μg×kg-1×min-1 for 3-7 days. Before the treatment and 1, 3, 7 days after treatment, researchers detected indexes of cardiac and renal function, the levels of N-terminal B-type natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), cardiac output (CO), pulmonary capillary wedge pressure (PCWP), central venous pressure (CVP), urea nitrogen (BUN), serum creatinine (SCr), and urine output; the renal function index was re-evaluated at 30 days after administration, and the time entering ICU again, re-admission, cardiovascular events were recorded.

RESULTS: 408 patients were enrolled, with 241 males and 167 females. Age range was 28-95 years, the average age was (63.0±15.8) years, and 50-70 years old accounted for 46.8%. Compared with the data before treatment, NT-proBNP, PCWP and CVP significantly decreased at 6 hours after treatment [NT-proBNP (μg×kg-1×min-1): 4 378.58±4 082.29 vs. 6 403.41±5 759.48, PCWP (mmHg, 1 mmHg = 0.133 kPa): 12.41±2.21 vs. 14.26±2.85 , CVP (mmHg): 10.63±2.62 vs. 11.45±3.45, all P < 0.05], and with the prolongation of injection, NT-proBNP, PCWP and CVP were gradually declined; CO 1 day after treatment (mL: 4.89±0.81 vs. 4.40±0.92) and LVEF 3 days after treatment (0.465±0.100 vs. 0.431±0.107) were significantly increased (both P < 0.05), and with the prolongation of injection, CO and LVEF were gradually increased. There were no obvious changes in BUN and SCr during the treatment, but 30 days after treatment, SCr was significantly lower than that pre-treatment (μmol/L: 110.98±47.40 vs. 132.62±75.60, P < 0.01). Compared with the data pre-treatment, urine output per hour was significantly increased at 3 hours after treatment (mL: 129.59±82.16 vs. 89.60±53.49, P = 0.000); urine output every 24 hours was significantly increased at day 1 and day 2 after administration (mL: 2 676.54±1 006.83, 2 678.74±975.97 vs. 2 150.36±283.76, both P < 0.01). In 7 days, the re-entry ICU rate was 2.7%, and the re-hospitalization rate was 2.88% within 30 days, re-cardiac failure rate was 1.43% in 30 days, and the overall fatality rate was 9.55% in 30 days.

CONCLUSIONS: The rhBNP can significantly improve heart function in patients with HF. And, it has a certain effect on renal function. The rhBNP is effective and safe for the treatment of cardiac insufficiency.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Feng X, Wu Y, Meng Y, et al. [Efficacy and safety of intravenous recombinant human brain natriuretic peptide in patients with severe heart failure: a prospective multicenter clinical study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017. PMID: 28625241. doi:10.3760/cma.j.issn.2095-4352.2017.06.009

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。